These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 29950829

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
    Rodallec A, Sicard G, Giacometti S, Carré M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.
    Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
    Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ.
    J Natl Cancer Inst; 2004 May 19; 96(10):739-49. PubMed ID: 15150302
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
    Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F.
    Int J Nanomedicine; 2011 May 19; 6():1903-12. PubMed ID: 21931485
    [Abstract] [Full Text] [Related]

  • 8. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization, in vitro and in vivo assessment.
    Raikwar S, Yadav V, Jain S, Jain SK.
    J Liposome Res; 2024 Jun 19; 34(2):239-263. PubMed ID: 37594466
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ.
    Anticancer Agents Med Chem; 2017 Jun 19; 17(1):48-56. PubMed ID: 27225450
    [Abstract] [Full Text] [Related]

  • 10. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
    Merlin JL, Barberi-Heyob M, Bachmann N.
    Ann Oncol; 2002 Nov 19; 13(11):1743-8. PubMed ID: 12419746
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.
    Lancet Oncol; 2018 Jan 19; 19(1):115-126. PubMed ID: 29175149
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
    McCormack PL.
    Drugs; 2013 Sep 19; 73(13):1491-502. PubMed ID: 23982598
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ.
    J Natl Cancer Inst; 2004 May 19; 96(10):759-69. PubMed ID: 15150304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.